Physician profile
Deidre Johnson
NPI 1730743329
$7,060.47
in general payments reported to CMS, 2019-2025
41 companies · $1,088 in 2025
The $1,088 reported for 2025 was more than what 88% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,248 · 2022: $1,364 · 2023: $1,240 · 2024: $2,120 · 2025: $1,088.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,051 · Travel and Lodging: $1,397.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,050.57 |
| Travel and Lodging | $1,397.32 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Intuitive Surgical, INC. | $1,397.32 | 2024 | |
| Abbvie INC. | $1,062.27 | 2021-2025 | |
| Pfizer INC. | $941.73 | 2021-2025 | |
| Novo Nordisk INC | $829.17 | 2021-2025 | Ozempic, Rybelsus, Wegovy |
| Lilly USA, LLC | $452.28 | 2021-2025 | Mounjaro, Zepbound, Kisunla |
| Merck Sharp & Dohme LLC | $402.23 | 2021-2025 | Verquvo, Belsomra, Capvaxive |
| Glaxosmithkline, LLC. | $290.30 | 2021-2025 | Trelegy Ellipta, Shingrix, Arexvy |
| Novartis Pharmaceuticals Corporation | $270.94 | 2021-2024 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $158.45 | 2021-2025 | Ofev, Jardiance, Synjardy |
| Currax Pharmaceuticals LLC | $135.48 | 2021-2024 | Contrave, Onzetra Xsail, Nexlizet |
| Astellas Pharma US INC | $126.50 | 2021-2023 | Myrbetriq |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $95.51 | 2021-2022 | |
| Horizon Therapeutics Plc | $91.14 | 2021-2022 | |
| Amarin Pharma, INC. | $66.79 | 2021-2022 | |
| Exact Sciences Corporation | $65.05 | 2023-2024 | Cologuard Collection Kit |
Show all 41 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Deidre Johnson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.